Springer Book Archives: eBooks only 8.99 each! Save now >>

Cancer Treatment and Research

Acute Myelogenous Leukemia

Genetics, Biology and Therapy

Editors: Nagarajan, Lalitha (Ed.)

Free Preview
  • Details the work of pioneers in the area of genetic mechanisms, targeted therapy, biology and mouse models for acute myelogenous leukemia

Buy this book

eBook $89.00
price for USA in USD (gross)
  • ISBN 978-0-387-69259-3
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $119.99
price for USA in USD
  • ISBN 978-0-387-69257-9
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
  • Usually dispatched within 3 to 5 business days.
Softcover $129.00
price for USA in USD
  • Customers within the U.S. and Canada please contact Customer Service at +1-800-777-4643, Latin America please contact us at +1-212-460-1500 (24 hours a day, 7 days a week). Pre-ordered printed titles are excluded from promotions.
  • Due: December 2, 2010
  • ISBN 978-1-4419-1299-2
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
About this book

Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages.

Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.

 

"The effective treatment of acute myelogenous leukemia remains a great challenge. This text reviews our understanding of the molecular and biologic basis of the disease. Leading investigators address advances in prognostication and therapeutic strategies that have significant promise."

Steven T. Rosen, M.D.
Series Editor

About the authors

Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas. 

Table of contents (15 chapters)

Table of contents (15 chapters)

Buy this book

eBook $89.00
price for USA in USD (gross)
  • ISBN 978-0-387-69259-3
  • Digitally watermarked, DRM-free
  • Included format: PDF, EPUB
  • ebooks can be used on all reading devices
  • Immediate eBook download after purchase
Hardcover $119.99
price for USA in USD
  • ISBN 978-0-387-69257-9
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
  • Usually dispatched within 3 to 5 business days.
Softcover $129.00
price for USA in USD
  • Customers within the U.S. and Canada please contact Customer Service at +1-800-777-4643, Latin America please contact us at +1-212-460-1500 (24 hours a day, 7 days a week). Pre-ordered printed titles are excluded from promotions.
  • Due: December 2, 2010
  • ISBN 978-1-4419-1299-2
  • Free shipping for individuals worldwide
  • Immediate ebook access, if available*, with your print order
Loading...

Recommended for you

Loading...

Bibliographic Information

Bibliographic Information
Book Title
Acute Myelogenous Leukemia
Book Subtitle
Genetics, Biology and Therapy
Editors
  • Lalitha Nagarajan
Series Title
Cancer Treatment and Research
Series Volume
145
Copyright
2010
Publisher
Springer-Verlag New York
Copyright Holder
Springer-Verlag New York
eBook ISBN
978-0-387-69259-3
DOI
10.1007/978-0-387-69259-3
Hardcover ISBN
978-0-387-69257-9
Softcover ISBN
978-1-4419-1299-2
Series ISSN
0927-3042
Edition Number
1
Number of Pages
IX, 280
Topics

*immediately available upon purchase as print book shipments may be delayed due to the COVID-19 crisis. ebook access is temporary and does not include ownership of the ebook. Only valid for books with an ebook version. Springer Reference Works are not included.